<DOC>
	<DOCNO>NCT01810939</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety patiromer ( investigational drug ) treatment hyperkalemia ( high serum potassium ) . The study also evaluate effect withdraw patiromer treatment assess whether chronic treatment patiromer prevent recurrence hyperkalemia . The safety patiromer treatment also evaluate .</brief_summary>
	<brief_title>A Two-Part , Single-Blind , Phase 3 Study Evaluating Efficacy Safety Patiromer Treatment Hyperkalemia ( OPAL )</brief_title>
	<detailed_description>There two part study , Part A Part B . Part A assessment 4 week dose patiromer treatment hyperkalemia ; Part B randomize , placebo-controlled , 8-week assessment withdrawal patiromer participant baseline serum potassium begin Part A ≥ 5.5 mEq/L respond 4 week treatment patiromer Part A . All participant receive patiromer Part A ; Part B participant randomize continue patiromer switch placebo . Total study participation 14 week ( include 2 week follow ) . The dose patiromer could titrate base participant 's serum potassium response .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperkalemia</mesh_term>
	<criteria>Males female age 18 80 Chronic kidney disease ( CKD ) eGFR 15 &lt; 60 mL/min/1.73m2 screen Hyperkalemia , define serum potassium value 5.1 &lt; 6.5 mEq/L screen Taking either AngiotensinConverting Enzyme ( ACE ) Inhibitor , Angiotensin II receptor blocker ( ARB ) , aldosterone antagonist ( AA ) medication Informed consent give Participants autoimmune relate chronic kidney disease lupus nephritis renal scleroderma/scleroderma renal crisis , mixed connective tissue disease renal involvement Participants uncontrolled Type 1 diabetes , define HbA1c &gt; 10.0 % , hospitalization treat hyper hypoglycemia past 3 month within previous 6 month participant Type 2 diabetes Participants severe heart failure , define NYHA ( New York Heart Association ) class IV Participants major surgery include thoracic cardiac , past 3 month , participant heart kidney transplant Participants significant cardiovascular cerebrovascular event past 2 month , cardiac arrest , myocardial infarction , stroke Participants BMI ≥ 40 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Treatment Hyperkalemia</keyword>
	<keyword>Hyperkalemia</keyword>
</DOC>